<DOC>
	<DOCNO>NCT01083251</DOCNO>
	<brief_summary>Abstract Telbivudine potent inhibitor HBV , due low genetic barrier resistance , high incidence resistance observe patient high baseline level replication detectable HBV DNA 24 week therapy ( A1 ) . Telbivudine might use patient good predictor response ( HBV DNA &lt; 2 X 106 IU/ ml , i.e . approximately 107 copies/ ml , 6.3 log 10 IU/ ml baseline ) verification HBV DNA suppression detection real time PCR assay 24 week . ( EASL Guidelines HBV 2009 ) The therapy Pegylated-interferon-alpha-2a consider standard care patient chronic hepatitis b viral infection . However , recent study Buster et al show sustained viral response ( SVR less 2000 iu.ml 6 month treatment ) ) obtain 8 % patient genotype D , 30 % genotype A , 20-25 % genotype B C ( 47 ) . Vitamin D potent immune-modulator ; show improve SVR combination peg interferone patient chronic HCV viral infection ( 48 ) . The impact vitamin D virologic response rate interferon-based treatment CHB unknown . The aim study therefore ass whether Vitamin D , add conventional peg therapy CHB , nucleotide analogue could improve treatment efficacy</brief_summary>
	<brief_title>The Beneficial Effect Vitamin D Supplement Peg Interferon Alpha 2a Telbivudine Monotherapy Patients With Chronic Hepatitis B Virus ( HBV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>patient eligible HBsAg positive least 6 month , patient HBeAg positive negative , patient increase serum ALT level 1 10 time upper limit normal ( ULN ) , patient serum HBVDNA level great 1.0 x 10E5 copies/mL ( 2.0 X 10E4 IUmL ) , patient finding liver biopsy within precede 12 month consistent presence chronic hepatitis B. decompensated liver disease , antiviral therapy within 6 month randomization , viral coinfections ( hepatitis C virus , hepatitis delta virus , human immunodeficiency virus ) , preexistent neutropenia thrombocytopenia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>HBV</keyword>
	<keyword>VITAMIN D</keyword>
	<keyword>PEGITERFERON</keyword>
	<keyword>Telbivudine</keyword>
</DOC>